Additionally, notable inter-group differences (≥10%) were found in aspects such as alanine aminotransferase increased, weight decreased, and hypomagnesemia, all of which were more prevalent in cetuximab β plus FOLFIRI group (Table 3). This evidence concerns the gene GPT and familial primary hypomagnesemia.